{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:31:17Z","timestamp":1757611877669,"version":"3.44.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Treating Acute Lymphoblastic Leukemia (ALL) in patients with genetic disorders poses significant challenges for onco-hematologists. Mucopolysaccharidosis type IVA (MPS-IVA) is a lysosomal storage disorder that clinically manifests with progressive and multi-systemic comorbidities, primarily affecting the bone, cartilage, spine, heart and lungs. We report a unique case of B-lineage ALL in a patient with MPS-IVA, who was successfully cured with a personalized chemo-radiotherapy approach. The treatment strategy aimed to balance a curative-intent chemotherapy attempt with the minimization of life-threatening complications. This case highlights the importance of individualized therapy in managing ALL in the context of complex comorbidities.<\/jats:p>","DOI":"10.3389\/fped.2025.1644720","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T04:12:22Z","timestamp":1756959142000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: Successful treatment of a patient presenting with a very rare association of acute lymphoblastic leukemia and mucopolysaccharidosis type IVA"],"prefix":"10.3389","volume":"13","author":[{"given":"Sofia Maria Carlotta","family":"Arnaboldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Caterina","family":"Faraguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Colombini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Gotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Rachele","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Crescitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Commone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","article-title":"TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children","volume":"36","author":"Qian","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1200\/JCO.23.00389","article-title":"Outcomes in children, adolescents, and young adults with down syndrome and ALL: a report from the children\u2019s oncology group","volume":"42","author":"Rabin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (morquio A disease): clinical review and current treatment","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol Genet Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","article-title":"Findings from the morquio A registry study (MARS) after 6 years: long-term outcomes of MPS IVA patients treated with elosulfase alfa","volume":"137","author":"Mitchell","year":"2022","journal-title":"Mol Genet Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"B9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0022-3476(69)80010-7","article-title":"Hepatorenal glycogenosis (type I glycogenosis) and carcinoma of the liver","volume":"74","author":"Zangeneh","year":"1969","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jmg.15.3.239","article-title":"Acute myelogenous leukaemia in Hurler\u2019s syndrome","volume":"15","author":"Chen","year":"1978","journal-title":"J Med Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.V104.11.1954.1954","article-title":"Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols","volume":"104","author":"Testi","year":"2004","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(04)01570-0","article-title":"Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin","volume":"5","author":"Jones","year":"2004","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835d7d85","article-title":"Optimizing asparaginase therapy for acute lymphoblastic leukemia","volume":"25","author":"Rizzari","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/bjh.16337","article-title":"Long-term outcome evaluation of medium\/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study","volume":"189","author":"Piette","year":"2020","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"Van Der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1644720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T04:12:22Z","timestamp":1756959142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1644720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":17,"alternative-id":["10.3389\/fped.2025.1644720"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1644720","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1644720"}}